Third Harmonic Bio to shutter; Future Pak once again targets Theratechnologiesnews2025-04-14T13:52:18+00:00April 14th, 2025|Endpoints News|
Argenx’s Vyvgart Hytrulo syringe is approved in the US; Opthea to cut 65% of staffnews2025-04-11T14:06:59+00:00April 11th, 2025|Endpoints News|
Idorsia’s blood pressure pill no longer requires a REMS; Solu raises $41Mnews2025-04-09T14:28:12+00:00April 9th, 2025|Endpoints News|
Rallybio ends development in rare disorder; ImmunityBio raises $75Mnews2025-04-08T14:17:56+00:00April 8th, 2025|Endpoints News|
Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workersnews2025-04-07T14:18:39+00:00April 7th, 2025|Endpoints News|
Sarepta indicates it’s safe to continue Elevidys dosing in Europe; Epsilogen buys TigaTxnews2025-04-04T14:28:47+00:00April 4th, 2025|Endpoints News|
MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund news2025-04-03T14:27:45+00:00April 3rd, 2025|Endpoints News|
Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurixnews2025-04-02T14:40:03+00:00April 2nd, 2025|Endpoints News|
Prazer Therapeutics raises $20M; Carisma lets go of most staffnews2025-04-01T14:19:29+00:00April 1st, 2025|Endpoints News|
LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drugnews2025-03-31T14:57:15+00:00March 31st, 2025|Endpoints News|
